Production, purification and characterization of recombinant human antithrombin III by Saccharomyces cerevisiae

详细信息    查看全文

• 作者：Maheswara Reddy Mallu ; Sandeep Vemula ; Srinivasa Reddy Ronda ; ^{rsr@kluniversity.in" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Biological activity ; Cell lysis ; Cross flow filtration ; Fed-batch fermentation ; Purification ; Secondary structure
• 刊名：Electronic Journal of Biotechnology
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：22
• 期：Complete
• 页码：81-89
• 全文大小：845 K

文摘

Antithrombin III (ATIII) is a protein that inhibits abnormal blood clots (or coagulation) by breaking down thrombin and factor Xa. ATIII helps to keep a healthy balance between hemorrhage and coagulation. The present work demonstrated the production, purification and characterization of recombinant human antithrombin (rhAT) from yeast Saccharomyces cerevisiae BY4741 was demonstrated. After expression of rhAT by S. cerevisiae, the biomass and rhAT concentration were analyzed through fed-batch fermentation process.

Results

In fed-batch fermentation, the biomass (maximum cell dry weight of 11.2 g/L) and rhAT concentration (312 mg/L) of the expressed rhAT were achieved at 84 h of cultivation time. The maximum cell lysis efficiency (99.89%) was found at 8 s sonication pulse and 7 mL lysis buffer volume. The rhAT protein solution was concentrated and partially purified using cross-flow filtration with the recovery yield and purity of 95 and 94%, respectively. The concentrated solution was further purified by the single step ion exchange chromatography with the recovery yield and purity of 55 and ≥ 98%, respectively. The purified rhAT was characterized by various analytical techniques, such as RP-HPLC, FT-IR, CD, SDS-PAGE, western blotting, and Liquid chromatography mass spectrometry (LC–MS) analysis. The biological activity of rhAT was analyzed as heparin cofactor to meet the therapeutic grade applications.

Conclusions

The simple, cost-effective and economically viable nature of the process used in the present study for the production of rhAT will be highly beneficial for the healthcare sector. This may also be used to produce other value-added therapeutic recombinant proteins expressed in S. cerevisiae, with greater effectiveness and ease.